News & Updates
Filter by Specialty:
Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.
Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022
Survivors of symptomatic COVID-19 likely to have impaired wellbeing
People who experienced symptomatic COVID-19 are more likely to suffer from feelings of nervousness, anxiousness, and tension than those who had oligosymptomatic disease, a recent study has found. Such an effect appears to be pronounced in women and younger survivors.
Survivors of symptomatic COVID-19 likely to have impaired wellbeing
04 Jun 2022
Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.
Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
04 Jun 2022
HRT use tied to reduced COVID-19 death risk
The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.
HRT use tied to reduced COVID-19 death risk
02 Jun 2022
Postjab nAb assessment at one’s fingertips
A group of researchers from Singapore has recently developed a finger stick blood test that can rapidly and semi-quantitatively assess the neutralizing antibody (nAb) response of people who have been vaccinated against COVID-19.
